The results of in vitro experiments revealed that rhein and erlotinib, when used in combination, inhibited the phosphorylation of STAT3 and EGFR in pancreatic cancer cell lines, thereby inhibiting the proliferation of pancreatic cancer cells. The gene discussed is STAT3; the disease is familial pancreatic carcinoma.